Related Experiment Video
Updated: Jan 22, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Pharmaceutical Management of Ovarian Cancer: Current Status
1Medicine and Science, Cancer Treatment Centers of America, 1331 East Wyoming Avenue, Philadelphia, PA, 19124, USA. maurie.markman@ctca-hope.com.
For over 20 years, platinum and taxane chemotherapy has been standard for ovarian cancer. Newer strategies include targeted therapies like bevacizumab, PARP inhibitors, and checkpoint inhibitors, improving patient outcomes.
Area of Science:
- Oncology
- Gynecologic Oncology
Background:
- Platinum and taxane chemotherapy has been the cornerstone for epithelial ovarian cancer for over two decades.
- Alternative administration routes and timing (neoadjuvant, intraperitoneal) have improved outcomes in specific patient groups.
- Second-line and later treatment strategies aim to prolong survival and enhance quality of life.
Purpose of the Study:
- To review current and emerging treatment strategies for epithelial ovarian cancer.
- To highlight the role of targeted therapies and immunotherapies in ovarian cancer management.
Main Methods:
- Review of established and novel therapeutic approaches in ovarian cancer.
- Analysis of clinical data on chemotherapy, anti-angiogenic agents, PARP inhibitors, and checkpoint inhibitors.
Main Results:
- Bevacizumab (anti-angiogenic) demonstrates clinical activity when combined with chemotherapy in various settings.
- Poly-(ADP-ribose) polymerase (PARP) inhibitors are effective as monotherapy or maintenance treatment.
- Checkpoint inhibitors are being investigated alone and in combination with other agents.
Conclusions:
- Ovarian cancer treatment is evolving beyond traditional chemotherapy.
- Combination therapies involving targeted agents and immunotherapies show promise for improved efficacy.
More Related Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
05:42Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
Related Concept Videos
Pharmaceutical Equivalents
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Marcia's Theory of Identity Status
Electrical Current
Ovarian Cycle
Factors Influencing Drug Absorption: Pharmaceutical Parameters